Literature DB >> 4038714

The concurrence of hypoparathyroidism provides new insights to the pathophysiology of X-linked hypophosphatemic rickets.

K W Lyles, E J Burkes, C R McNamara, J M Harrelson, J P Pickett, M K Drezner.   

Abstract

Controversy exists over the role that PTH and extracellular fluid calcium concentration may play in modulation of the renal phosphate transport defect in X-linked hypophosphatemic rickets. In previous studies, administration of PTH to affected subjects resulted in an increase or no effect on renal phosphate excretion, while calcium infusion increased renal tubular phosphate transport. In contrast, patients with X-linked hypophosphatemic rickets and hyperparathyroidism have no change in their renal phosphate wasting after parathyroidectomy. However, none of these were permanently hypoparathyroid postoperatively. We describe a patient with idiopathic hypoparathyroidism in whom we proved the coexistence of X-linked hypophosphatemic rickets using family history and dental abnormalities. Initially, the patient had a mean serum calcium level of 5.6 +/- 0.07 (+/- SE) mg/dl and a renal tubular maximum for reabsorption of phosphate per liter glomerular filtrate (TmP/GFR) of 6.5 +/- 0.46 mg/dl. Hypoparathyroidism was confirmed, and therapy with vitamin D (50,000 U/day) and calcium (1,000 mg/day) was begun. On this regimen, serum calcium rose to 8.1 +/- 0.2 mg/dl, and TmP/GFR declined to 2.59 +/- 0.12 mg/dl. Bone biopsy revealed the persistence of osteomalacia. Subsequently, therapy with 1,25-dihydroxyvitamin D3 (1.0 microgram/day) was initiated, and serum calcium rose to 9.6 +/- 0.07 mg/dl, and TmP/GFR declined to 1.79 +/- 0.16 mg/dl. The prevailing serum calcium level correlated inversely with the TmP/GFR (r2 = 0.91; P less than 0.001). These data indicate that calcium and/or PTH are involved in modulation of the renal phosphate transport defect in X-linked hypophosphatemic rickets.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038714     DOI: 10.1210/jcem-60-4-711

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  M K Drezner
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.

Authors:  Thomas O Carpenter; Elizabeth A Olear; Jane H Zhang; Bruce K Ellis; Christine A Simpson; David Cheng; Caren M Gundberg; Karl L Insogna
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

3.  Dental Findings in Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism: A Systematic Review.

Authors:  Jane Hejlesen; Line Underbjerg; Hans Gjørup; Agnes Bloch-Zupan; Tanja Sikjaer; Lars Rejnmark; Dorte Haubek
Journal:  Front Physiol       Date:  2018-06-19       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.